‘The Swedish Drug Discovery and Development Pipeline 2020’ report was launched yesterday in Stockholm, exploring 148 pharma and biotech companies developing new drugs and 420 R&D projects within oncology, neurology, endocrinology/metabolism and infection. With a special focus on drug delivery, cell- & gene therapy and rare diseases, the report presents highlights from one of the world’s leading life science clusters.
The report shows that the Swedish drug discovery and development pipeline is expanding and maturing, with more projects starting up and moving into later phases, while also increasingly attracting international capital.
“Since the last report back in 2016, we have seen growth in particular among companies with projects in clinical phases. More companies have reached phase III or are close to market approval of their products,” said SwedenBIO’s Sara Gunnerås, editor of the report, in a press release.
With 48% of Sweden’s pharma and biotech companies, the Stockholm-Uppsala region is one of four hotspots in Sweden for drug discovery and development. With half of the companies already having attracted international venture capital, the Swedish drug discovery and development pipeline is gaining increased attention from abroad.
“The number of projects in the Stockholm-Uppsala region has increased significantly in the last years, contributing to major business opportunities for international companies that are looking to invest in the Stockholm region. It sends a clear signal that our life science ecosystem is one of the world’s most interesting, in particular within our strongest sectors oncology, neurology, metabolic diseases and infection,” says Ylva Hultman, Head of Life Science Investment Promotion at Invest Stockholm.
Invest Stockholm, in close collaboration with Business Sweden, provides support in finding business opportunities, such as joint ventures, acquisitions and venture capital, as well as establishment services for companies that wish to relocate and expand in the Stockholm region.
For updated investment cases and more information about world-leading research and business opportunities in the Stockholm-Uppsala region, please contact:
Ylva Hultman, Head of Life Science Investment Promotion, Invest Stockholm
+46 (0)70-472 80 65, email@example.com
About the report
The report is produced by SwedenBIO in cooperation between and with financial support from Invest Stockholm, Invest in Skåne, Business Region Göteborg, Business Sweden and Vinnova – Sweden’s innovation acency.
The report is available for download under related media.
SwedenBIO, the trade association for the Swedish life science sector has more than 260 members operating across all sub-sectors from pharmaceutical, biotechnology, medical technology to diagnostics. SwedenBIO serves the entire life science industry in Sweden and is a member-driven, private, non-profit organization. The main objective is to contribute to improving the conditions for the life science industry for the benefit of industry growth and business development. Sweden’s life science industry accounts for 20% of Sweden's net exports.
Invest Stockholm is the official investment promotion agency of Stockholm. We work with the marketing and development of the Stockholm region as a business destination under the brand Stockholm – The Capital of Scandinavia. Invest Stockholm is a subsidiary of Stockholm Business Region, owned by the city of Stockholm.